S2Medical (S2M.ST) Stock Analysis & AI Equity Report
S2Medical (S2M.ST) overview
S2Medical (S2M.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, S2Medical reported revenue of SEK 14.4m and operating profit of SEK -2.7m; the year-end share price was 0.01 SEK and market capitalisation was SEK 9.2m. S2Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get S2Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About S2Medical
S2Medical AB (publ) is a Swedish medical technology company focused on wound healing, infection control and cosmeceuticals. It develops and sells products including Epiprotect, IvaQ and Instagraft, and manufactures parts of its portfolio in-house. The company’s offerings are aimed at burns, chronic wounds and other hard-to-heal conditions.
Generate the S2Medical report
S2Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for S2Medical and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.